Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

1.6K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.6K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.0K
Cross-reactivity00:42

Cross-reactivity

32.7K
Overview
32.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.

The Journal of experimental medicine·2024
Same author

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.

EBioMedicine·2024
Same author

Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.

The Journal of infectious diseases·2024
Same author

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.

Nature communications·2024
Same author

Reflections on Progress in Genital Herpes Therapy and Prevention 1997 to 2024.

Sexually transmitted diseases·2024
Same author

Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine.

JCI insight·2024

Related Experiment Video

Updated: Dec 30, 2025

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.6K

Broadly Neutralizing Antibodies for HIV Prevention.

Shelly T Karuna1, Lawrence Corey1,2

  • 1HIV Vaccine Trials Network, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA; email: mkaruna@fredhutch.org, lcorey@fredhutch.org.

Annual Review of Medicine
|January 28, 2020
PubMed
Summary

Broadly neutralizing antibodies (bnAbs) show promise for HIV prevention and therapy. Advancements in antibody engineering are enhancing their effectiveness and potential for widespread clinical use.

Keywords:
HIV preventionbnAbsbroadly neutralizing antibodiespassive immunization

More Related Videos

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.1K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

12.1K

Related Experiment Videos

Last Updated: Dec 30, 2025

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.6K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.1K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

12.1K

Area of Science:

  • Immunology
  • Virology
  • Infectious Diseases

Background:

  • Over a dozen potent broadly neutralizing antibodies (bnAbs) targeting HIV envelope protein epitopes have been identified.
  • These bnAbs demonstrate in vitro neutralization capabilities and have shown prevention efficacy in preclinical studies.
  • Early human trials indicate favorable safety and pharmacokinetic profiles for bnAbs.

Purpose of the Study:

  • To review the advancements in broadly neutralizing antibodies (bnAbs) for HIV prevention and therapy.
  • To discuss the development of antibody combinations and engineered antibodies.
  • To assess the future potential of human-derived monoclonal antibodies in clinical settings.

Main Methods:

  • Identification and characterization of potent bnAbs against HIV envelope protein epitopes.
  • Evaluation of in vitro neutralization profiles and preclinical prevention efficacy.
  • Assessment of safety and pharmacokinetic profiles in early human clinical trials.
  • Development and evaluation of antibody combinations, multi-specific bnAbs, and Fc-engineered bnAbs.

Main Results:

  • Multiple bnAbs have been identified with defined neutralization profiles.
  • bnAbs have demonstrated prevention efficacy in preclinical models and favorable safety in early human trials.
  • Fc region engineering has improved bnAb half-life, mucosal concentrations, and effector functions, enhancing preventative and therapeutic potential.
  • Combinations of bnAbs and multi-specific bnAbs show improved breadth and potency.

Conclusions:

  • Broadly neutralizing antibodies (bnAbs) represent a significant advancement in HIV prevention and therapy.
  • Fc engineering and antibody combinations are enhancing the efficacy and therapeutic potential of bnAbs.
  • Human-derived monoclonal antibodies are poised for integration into primary care for viral infection prevention and treatment.